Generating β-cells in vitro: progress towards a Holy Grail

Area of Science:

• Regenerative Medicine
• Developmental Biology
• Stem Cell Biology

Background:

• Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia.
• Current treatments like pancreatic or islet transplantation face limitations due to organ scarcity.
• Alternative strategies for generating functional beta-cells are urgently needed.

Purpose of the Study:

• To review current advancements in generating scalable, functional beta-cells for diabetes treatment.
• To explore the potential of human pluripotent stem cells and cell reprogramming for beta-cell replacement therapy.

Main Methods:

• Utilizing developmental biology principles to guide human pluripotent stem cell differentiation into pancreatic progenitor cells (PPCs) in vitro.
• Employing small molecules, growth factors, and morphogens for stepwise cell differentiation.
• Investigating cell reprogramming of adult cell lineages (e.g., skin, liver) into functional beta-like cells.

Main Results:

• PPCs generated in vitro can mature into functional islet-like tissues in vivo, containing diverse endocrine hormone cells.
• Transplanted PPCs have demonstrated the ability to reverse hyperglycemia in animal models of diabetes.
• Reprogramming of non-pancreatic adult cells into beta-like cells shows promise for alternative therapeutic avenues.

Conclusions:

• While fully functional beta-cells in vitro remain a challenge, PPCs and reprogrammed adult cells represent viable intermediate strategies for diabetes cell therapy.
• Immune isolation of transplanted cells is crucial to prevent host immune rejection, with ongoing research into immune-isolation devices.
• Future cell therapies aim to provide a scalable and potentially curative treatment for diabetes, reducing reliance on immunosuppressive drugs.